Drug firm Jubilant Life Sciences has received final approval from the US health regulator for generic anti-hypertensive Valsartan tablets and the company plans to launch the product immediately. [image: Representational Image] <http://s2.firstpost.in/wp-content/uploads/2014/02/PHARMA-REUTERS1.jpg>
Representational Image The company has received final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application for Valsartan tablets USP in the strengths of 40 mg, 80 mg, 160 mg and 320 mg, Jubilant Life Sciences said in a filing to BSE. "We expect to launch this product immediately," it added. The product is generic version of Diovan tablets of pharma major Novartis and is used as an anti-hypertensive, Jubilant Life Sciences said. "The current annualised US market size for Valsartan tablets USP, 40 mg, 80 mg, 160 mg, and 320 mg as per IMS is $2 billion," it added. As on September 30, 2014, Jubilant Life Sciences had a total of 781 filings for formulations of which 322 have been approved in various regions globally. This includes 72 ANDAs filed in the US and 46 dossier filings in Europe, Jubilant Life Sciences said. -- Kindly email stock reports at STOCKRESEARCHER@googlegroups.com For sharing knowledge -- NIFTYVIEWS.COM NOW A FREE OPEN SOURCE WEBSITE. http://www.niftyviews.com/ Disclaimer :- "The opinions expressed by the members on this board are based on their individual experience and perceptions and to share information with other members with the best of intentions to help fellow members in investment decisions as equity investment is a risky venture.The administrator of www.Niftyviews.com just provide a platform for the authors to express their opinion and take no guarantee for the genuineness of the same."ANY member of this forum doesnt prepare or publish any research report; or ii. provide research report; or iii. make 'buy/sell/hold' recommendation; or iv. give price target; --- You received this message because you are subscribed to the Google Groups "Niftyviews.com" group. To unsubscribe from this group and stop receiving emails from it, send an email to stockresearcher+unsubscr...@googlegroups.com. For more options, visit https://groups.google.com/d/optout.
